GPP2 Antibody

Glycoprotein 2 (GP2)

GP2 is a glycoprotein expressed in pancreatic acinar cells and intestinal microfold (M) cells. It exists in two forms:

• Membrane-bound GP2: Anchored via glycosylphosphatidylinositol (GPI) to secretory granule membranes .

• Secretory GP2: Released into pancreatic secretions and intestinal lumen, binding pathogens to prevent mucosal invasion .

Antibody Targets:

• Anti-GP2 antibodies (IgA/IgG) recognize epitopes on GP2’s C-terminal GPI anchor and N-linked glycosylation sites .

• These autoantibodies are implicated in Crohn’s disease (CD) and primary sclerosing cholangitis (PSC) .

G Protein Pathway Suppressor 2 (GPS2)

GPS2 is a 37 kDa nuclear protein involved in transcriptional regulation and immune signaling. Commercial antibodies (e.g., ab153986) target recombinant human GPS2 (amino acids 1–300) .

Anti-GP2 Antibodies in Disease

Diagnostic Performance:

• Crohn’s vs. Ulcerative Colitis: Anti-GP2 IgA achieves 80% specificity (AUC 0.74) .

• PSC Prognosis: Combined anti-GP2 IgA and PR3-ANCA positivity increases mortality risk (HR 3.2) .

Research Tools: Anti-GPS2 Antibodies

The GPS2 antibody (ab153986) is validated for:

• Applications: Western blot (1:500 dilution), immunohistochemistry (1:500) .

• Specificity: Detects endogenous GPS2 in A431 and HeLa cell lysates .

Performance Data:

GP2 in Mucosal Immunity

• Binds Escherichia coli fimbriae, mimicking urinary Tamm-Horsfall protein (53% sequence similarity) .

• Facilitates antigen sampling by M cells in Peyer’s patches .

GPS2 in Immune Regulation

• Modulates NF-κB and JNK pathways, suppressing pro-inflammatory cytokines .

Therapeutic Implications

• GP2-Targeted Therapies: Blocking anti-GP2 antibodies may reduce intestinal inflammation .

• GPS2 in Oncology: Downregulation correlates with tumor progression, suggesting diagnostic potential .

Table 1: Anti-GP2 Antibody Prevalence in PSC

Table 2: GP2 Plasma Levels in Pancreatic Diseases